Talk
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery
Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Kam Dhaliwal and Thomas Moreau discuss how bit.bio are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Listen to our talk at ELRIG Drug Discovery Digital to learn how bit.bio’s opti-ox™ technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.
2020
Dr Thomas Moreau | Head of Research | bit.bio
Kam Dhaliwal | SVP Strategic Alliances | bit.bio
bit.bio talk at ELRIG Drug Discovery Digital
Download resource